_0001.png)
_0003.gif)
_0007.png)
_0006.gif)
_0005.png)
Current modes of drug delivery burden the entire body with high concentrations of the drug. This is due to the fact that only a small fraction of the active pharmaceutical agent reaches its target, thus bearing the risk of toxic cellular, organ-specific or systemic side effects. Such collateral damage can be considerably reduced or even excluded by employing Targeted Drug Delivery Systems that effectively reach those cell populations in which the active pharmaceutical ingredient is supposed to unfold its cell-specific activity.
RBT’s TargoSphere® technology for drug delivery is well established. The system addresses all C-type lectin receptors (CLRs) - such as, prominently, CD209/CD-SIGN - for specifically and efficiently delivering therapeutic payloads. CLR-positive cell populations that have been shown to be specifically reached by the TargoSphere® are (i) myeloid antigen-presenting cells (APCs) that comprise immature and mature dendritic cells, blood monocytes, and tissue macrophages as well as (ii) the sinusoidal endothelial cells and hepatic stellate cells of the liver.
Evidentially, APCs are the most important class of immune cells: They not only initiate and direct all antigen-specific immune responses, but they are also responsible for linking the adaptive and innate branches of the immune system. Thus, APCs are most attractive therapeutic target cells. Specifically, by addressing these cells RBT’s technologies open up the possibility of developing new highly focused and antigen-specific vaccinations and therapies for infectious, malignant, chronic inflammatory, parasitic and autoimmune diseases.
Moreover, the fact that hepatic sinusoidal and stellate cells in addition to APCs are also targeted is essential for efficiently eliminating infectious reservoirs of HCV as well as HIV, because both viruses are known to form sanctuaries in these cell populations from which they continuously trans-infect those organ-resident or circulating cell populations in which active viral propagation occurs.
Additionally, because RBT’s TargoSphere® technologies enable controlled delivery of active compounds into APC target cells, there is a clear development potential for: (i) substantially enhancing the therapeutic efficacy of existing approved drugs that are currently applied in a non-targeted manner but may show significant evidence of generalized systemic toxicities; and (ii) highly selectively shuttling biologically active substances into APCs such as novel vaccines.
RBT’s TargoSphere® technology for drug delivery is well established. The system addresses all C-type lectin receptors (CLRs) - such as, prominently, CD209/CD-SIGN - for specifically and efficiently delivering therapeutic payloads. CLR-positive cell populations that have been shown to be specifically reached by the TargoSphere® are (i) myeloid antigen-presenting cells (APCs) that comprise immature and mature dendritic cells, blood monocytes, and tissue macrophages as well as (ii) the sinusoidal endothelial cells and hepatic stellate cells of the liver.
Evidentially, APCs are the most important class of immune cells: They not only initiate and direct all antigen-specific immune responses, but they are also responsible for linking the adaptive and innate branches of the immune system. Thus, APCs are most attractive therapeutic target cells. Specifically, by addressing these cells RBT’s technologies open up the possibility of developing new highly focused and antigen-specific vaccinations and therapies for infectious, malignant, chronic inflammatory, parasitic and autoimmune diseases.
Moreover, the fact that hepatic sinusoidal and stellate cells in addition to APCs are also targeted is essential for efficiently eliminating infectious reservoirs of HCV as well as HIV, because both viruses are known to form sanctuaries in these cell populations from which they continuously trans-infect those organ-resident or circulating cell populations in which active viral propagation occurs.
Additionally, because RBT’s TargoSphere® technologies enable controlled delivery of active compounds into APC target cells, there is a clear development potential for: (i) substantially enhancing the therapeutic efficacy of existing approved drugs that are currently applied in a non-targeted manner but may show significant evidence of generalized systemic toxicities; and (ii) highly selectively shuttling biologically active substances into APCs such as novel vaccines.
RBT´s Science and Technology
_0025.png)
- Home
- About us
- Research and Development
- Publications
- Partnerships
- Media
- FAQ
- Careers
- Contact
